Coronavirus Disease (COVID-19)-Original Article
 

COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care

Abstract

Abstract Abstract Abstract Abstract

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 2020;395(10223):507-13.
2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020:1-3.
3. Beutel G, Wiesner O, Eder M, Hafer C, Schneider AS, Kielstein JT, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care. 2011;15(2):R80.
4. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147-63.
5. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020:105954.
6. Takeda S, Munakata R, Abe S, Mii S, Suzuki M, Kashiwada T, et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 2010;36(5):906.
7. Shimizu T, Hanasawa K, Sato K, Umeki M, Koga N, Naganuma T, et al. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch Surg. 2009;394(2):303.
8. Ronco C, Reis T, De Rosa S. Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum.Blood Purif. 2020;49(3):255-8.
9. Kaçar CK, Uzundere O, Kandemir D, Yektaş A. Efficacy of HA330 Hemoperfusion Adsorbent in Patients Followed in the Intensive Care Unit for Septic Shock and Acute Kidney Injury and Treated with Continuous Venovenous Hemodiafiltration as Renal Replacement Therapy. Blood Purif. 2020:1-9.
10. Poli EC, Rimmele T, Schneider AG. Hemoadsorption with CytoSorb®. Intensive Care Med. 2019;45(2):236-9.
11. Reiter K, Bordoni V, Dall’Olio G, Ricatti MG, Soli M, Ruperti S, et al. In vitro removal of therapeutic drugs with a novel adsorbent system.Blood Purif. 2002;20(4):380-8.
12. Szczeklik W, Wawrzycka K, Włudarczyk A, Sega A, Nowak I, Seczyńska B, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45(1):7-13.
13. Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, et al. Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients.BMCAnesthesiol. 2014;14(1):24.
14. Ghannoum M, Bouchard J, Nolin TD, Ouellet G, Roberts DM, editors. Hemoperfusion for the treatment of poisoning: technology, determinants of poison clearance, and application in clinical practice. Semin Dial; 2014: Wiley Online Library.
15. La Manna G, Donati G. Coupled plasma filtration adsorption: a multipurpose extracorporeal detoxification therapy. Blood purif. 2018;46:228-38.
Files
IssueVol 19, No S1 (2020) QRcode
SectionCoronavirus Disease (COVID-19)-Original Article
Published2020-05-17
DOI https://doi.org/10.18502/ijaai.v19i(s1.r1).2848
PMID32534513
Keywords
No Keywords

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Esmaeili Vardanjani A, Moayedi S, Golitaleb M. COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care. Iran J Allergy Asthma Immunol. 19(S1):7-9.